Advertisement
Advertisement

VNDA

VNDA logo

Vanda Pharmaceuticals Inc.

7.54
USD
Sponsored
-0.24
-3.07%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

7.63

+0.09
+1.25%

VNDA Earnings Reports

Positive Surprise Ratio

VNDA beat 28 of 38 last estimates.

74%

Next Report

Date of Next Report
Feb 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$60.46M
/
-$1.35
Implied change from Q3 25 (Revenue/ EPS)
+7.47%
/
+255.26%
Implied change from Q4 24 (Revenue/ EPS)
+13.68%
/
+1587.50%

Vanda Pharmaceuticals Inc. earnings per share and revenue

On Oct 29, 2025, VNDA reported earnings of -0.38 USD per share (EPS) for Q3 25, beating the estimate of -0.46 USD, resulting in a 17.82% surprise. Revenue reached 56.26 million, compared to an expected 59.91 million, with a -6.09% difference. The market reacted with a -20.15% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -1.35 USD, with revenue projected to reach 60.46 million USD, implying an increase of 255.26% EPS, and increase of 7.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Vanda Pharmaceuticals Inc. reported EPS of -$0.38, beating estimates by 17.82%, and revenue of $56.26M, -6.09% below expectations.
The stock price moved down -20.15%, changed from $5.41 before the earnings release to $4.32 the day after.
The next earning report is scheduled for Feb 11, 2026.
Based on 6 analysts, Vanda Pharmaceuticals Inc. is expected to report EPS of -$1.35 and revenue of $60.46M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement